Insulin receptor substrate-1 is an important mediator of ovarian cancer cell growth suppression by all-trans retinoic acid.

There is a need to identify more effective drugs for the treatment of ovarian cancer as it is the leading cause of death among gynecologic tumors. All-trans retinoic acid (ATRA), a natural retinoid, arrests the growth of CA-OV3 ovarian carcinoma cells in G(0)-G(1). Because the insulin-like growth factor-I receptor has been implicated in the proliferation of various tumors, we investigated its potential role in the suppression of ovarian cancer cell growth by ATRA. Our studies revealed that insulin receptor substrate-1 (IRS-1) protein levels decrease in CA-OV3 cells on ATRA treatment, whereas no differences in IRS-1 levels were seen in the ATRA-resistant SK-OV3 cells. Moreover, CA-OV3 clones overexpressing IRS-1 were growth inhibited less by ATRA, whereas SK-OV3 clones in which levels of IRS-1 were reduced by expression of antisense IRS-1 became sensitive to growth inhibition by ATRA treatment. Studies to determine the mechanism by which ATRA reduced IRS-1 expression showed that ATRA altered steady-state levels of IRS-1 mRNA and the stability of IRS-1 protein. Finally, the role of IRS-1 as a potential molecular target of ATRA in ovarian tumors was assessed by immunohistochemistry in an ovarian cancer tissue array. Compared with normal ovary, the majority of malignant epithelial ovarian tumors overexpressed IRS-1. Thus, there seems to be a correlation between IRS-1 expression and malignancy in ovarian tumors. Our results suggest that IRS-1 is in fact an important growth-regulatory molecule that can be a potential effective target for chemotherapeutic intervention with growth-suppressive agents, including retinoids.

[1]  D. Soprano,et al.  Reduction of both RAR and RXR levels is required to maximally alter sensitivity of CA-OV3 ovarian tumor cells to growth suppression by all-trans-retinoic acid. , 1997, Experimental cell research.

[2]  R. Ozols,et al.  Challenges for chemotherapy in ovarian cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  E. Dmitrovsky,et al.  Retinoic Acid Promotes Ubiquitination and Proteolysis of Cyclin D1 during Induced Tumor Cell Differentiation* , 1999, The Journal of Biological Chemistry.

[4]  S. Vuocolo,et al.  p27/Kip1 mediates retinoic acid‐induced suppression of ovarian carcinoma cell growth , 2004, Journal of cellular physiology.

[5]  E. Purev,et al.  Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid , 2006, Oncogene.

[6]  末岡 尚子.  Posttranslational Mechanisms Contribute to the Suppression of Specific Cyclin : CDK Complexes by All-Trans Retinoic Acid in Human Bronchial Epithelial Cells , 2000 .

[7]  J. Dupont,et al.  Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects , 2001, Molecular pathology : MP.

[8]  G. Tonini,et al.  p27Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation , 2000, Oncogene.

[9]  A. Giordano,et al.  Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression , 2001, Oncogene.

[10]  Jiong Wu,et al.  Molecular Mechanism of Insulin-Induced Degradation of Insulin Receptor Substrate 1 , 2002, Molecular and Cellular Biology.

[11]  Leslie M. Shaw,et al.  Suppression of Insulin Receptor Substrate 1 (IRS-1) Promotes Mammary Tumor Metastasis , 2006, Molecular and Cellular Biology.

[12]  M. Sułkowska,et al.  Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases , 2005, Journal of Clinical Pathology.

[13]  Y. Kido,et al.  Distinct and overlapping functions of insulin and IGF-I receptors. , 2001, Endocrine reviews.

[14]  J. Wands,et al.  A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. , 1996, The Journal of clinical investigation.

[15]  S. Andò,et al.  Expression of nuclear insulin receptor substrate 1 in breast cancer , 2006, Journal of Clinical Pathology.

[16]  R. Baserga,et al.  IGF-I receptor signalling in transformation and differentiation , 2001, Molecular pathology : MP.

[17]  F. Peruzzi,et al.  MINI REVIEW THE IGF-1 RECEPTOR IN CANCER BIOLOGY , 2003 .

[18]  S. Byron,et al.  Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells , 2006, British Journal of Cancer.

[19]  Y. Chang,et al.  Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer. , 2006, Oncology reports.

[20]  D. Yee,et al.  Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. , 1991, Cancer research.

[21]  E. Surmacz,et al.  Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Adrian V. Lee,et al.  Insulin-Like Growth Factor I-Induced Degradation of Insulin Receptor Substrate 1 Is Mediated by the 26S Proteasome and Blocked by Phosphatidylinositol 3′-Kinase Inhibition , 2000, Molecular and Cellular Biology.

[23]  J. Bartek,et al.  Protein Phosphatase 2A Associates with Rb2/p130 and Mediates Retinoic Acid-induced Growth Suppression of Ovarian Carcinoma Cells* , 2003, Journal of Biological Chemistry.

[24]  J. Chen,et al.  Transformation by the simian virus 40 T antigen is regulated by IGF-I receptor and IRS-1 signaling , 2006, Oncogene.

[25]  M. White,et al.  The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. , 1998, Current topics in microbiology and immunology.

[26]  E. Musgrove,et al.  Retinoic Acid-mediated Growth Arrest Requires Ubiquitylation and Degradation of the F-box Protein Skp2* , 2001, The Journal of Biological Chemistry.

[27]  Shujian Wu,et al.  Critical role of both retinoid nuclear receptors and retinoid-X-receptors in mediating growth inhibition of ovarian cancer cells by all-trans retinoic acid , 1998, Oncogene.

[28]  S. Hilsenbeck,et al.  Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. , 1999, Molecular endocrinology.

[29]  L. Shaw,et al.  Divergent Roles for IRS-1 and IRS-2 in Breast Cancer Metastasis , 2007, Cell cycle.

[30]  M. White,et al.  Phosphorylation of Ser307 in Insulin Receptor Substrate-1 Blocks Interactions with the Insulin Receptor and Inhibits Insulin Action* , 2002, The Journal of Biological Chemistry.

[31]  J. Goldberg,et al.  Insulin-induced insulin receptor substrate-1 degradation is mediated by the proteasome degradation pathway. , 1999, Diabetes.

[32]  Adrian V. Lee,et al.  Oncogenic Transformation by the Signaling Adaptor Proteins Insulin Receptor Substrate (IRS)-1 and IRS-2 , 2007, Cell cycle.

[33]  W. Miller,et al.  Retinoic acid mediates degradation of IRS-1 by the ubiquitin–proteasome pathway, via a PKC-dependant mechanism , 2004, Oncogene.

[34]  Shujian Wu,et al.  Retinoids and ovarian cancer , 2000, Journal of cellular physiology.

[35]  Takemi Tanaka,et al.  Involvement of all-trans-retinoic acid in the breakdown of retinoic acid receptors α and γ through proteasomes in mcf-7 human breast cancer cells , 2001 .

[36]  R. Baserga.  The IGF-I receptor in cancer research. , 1999, Experimental cell research.

[37]  M. Prisco,et al.  Differential roles of IRS‐1 and SHC signaling pathways in breast cancer cells , 1997, International journal of cancer.

[38]  Roger Davis,et al.  The c-Jun NH2-terminal Kinase Promotes Insulin Resistance during Association with Insulin Receptor Substrate-1 and Phosphorylation of Ser307 * , 2000, The Journal of Biological Chemistry.

[39]  E. Wickstrom,et al.  RNAi‐mediated silencing of insulin receptor substrate 1 (IRS‐1) enhances tamoxifen‐induced cell death in MCF‐7 breast cancer cells , 2006, Journal of cellular biochemistry.

[40]  F. Modugno.  Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. , 2003, Gynecologic oncology.

[41]  M. Pollak,et al.  Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. , 2006, Gynecologic oncology.

[42]  W. Miller,et al.  Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway , 2003, Oncogene.

[43]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[44]  Y. Li,et al.  Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. , 2002, Cancer research.

[45]  A. Benner,et al.  Down‐regulation of insulin‐like growth factor‐I receptor and insulin receptor substrate‐1 expression in advanced human breast cancer , 2000, International journal of cancer.

[46]  Shujian Wu,et al.  All-trans-retinoic acid blocks cell cycle progression of human ovarian adenocarcinoma cells at late G1. , 1997, Experimental cell research.

[47]  Y. Le Marchand-Brustel,et al.  Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. , 2005, Biochimie.

[48]  R. Roth,et al.  Modulation of human insulin receptor substrate-1 tyrosine phosphorylation by protein kinase Cdelta. , 2004, The Biochemical journal.